Analysts expect ESSA Pharma Inc. (CVE:EPI) to report $-0.57 EPS on December, 10.They anticipate $1.63 EPS change or 74.09 % from last quarter’s $-2.2 EPS. After having $-0.65 EPS previously, ESSA Pharma Inc.’s analysts see -12.31 % EPS growth. The stock decreased 13.41% or $0.59 during the last trading session, reaching $3.81. About 100 shares traded. ESSA Pharma Inc. (CVE:EPI) has 0.00% since November 17, 2017 and is . It has underperformed by 15.62% the S&P500.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $24.05 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.